FGL vs Semax
A side-by-side research comparison of FGL and Semax across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | FGL | Semax |
|---|---|---|
| Full name | FGL (NCAM-Derived Peptide) | Semax (ACTH 4-10 analog) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Research compound |
| Mechanism | Mimics NCAM FG loop interacting with FGFR1 to promote LTP, neurite outgrowth, neuronal survival, and presynaptic function enhancement. | Activates MC3/4R, increases BDNF and NGF, modulates dopamine/serotonin, enhances neuronal survival via TrkB, and promotes CREB-mediated neuroplasticity. |
| Molecular weight | ~1,800 Da | 813.9 Da |
| Half-life | 4-8 hours | 3-5 min (systemic) / extended (intranasal) |
| Bioavailability | Moderate (SubQ, partial BBB crossing) | Moderate (intranasal) |
| Typical dose | 1-5 mg/kg (research) | 200-600 mcg per dose |
| Frequency | Daily or every other day | 2-3x daily |
| Route | Subcutaneous | Intranasal drops/spray |
FGL reported benefits
- Synaptic plasticity
- LTP facilitation
- Memory improvement
- Neurotrophic effects
- FGFR activation
Semax reported benefits
- Enhanced attention/focus
- Memory improvement
- Neuroprotection (stroke)
- BDNF/NGF upregulation
- Improved learning
- Optic nerve support
Related comparisons
Research and educational reference only. Not medical advice.